![Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson's disease: A prospective analysis of Thai Apomorphine Registry - MDS Abstracts Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson's disease: A prospective analysis of Thai Apomorphine Registry - MDS Abstracts](http://www.mdsabstracts.org/wp-content/uploads/2020/09/0417_0603_001621_006.png)
Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson's disease: A prospective analysis of Thai Apomorphine Registry - MDS Abstracts
![PDF) Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease PDF) Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease](https://www.researchgate.net/publication/321628710/figure/tbl1/AS:863948807102465@1582992855321/Currently-marketed-apomorphine-formulations_Q320.jpg)
PDF) Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
![Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study | SpringerLink Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40120-021-00251-6/MediaObjects/40120_2021_251_Fig1_HTML.png)
Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study | SpringerLink
![Effects of apomorphine at dose 5 and 10 mg/kg on stereotypies in trace... | Download Scientific Diagram Effects of apomorphine at dose 5 and 10 mg/kg on stereotypies in trace... | Download Scientific Diagram](https://www.researchgate.net/profile/Marius-Hoener/publication/263097544/figure/fig3/AS:392372136497156@1470560215328/Effects-of-apomorphine-at-dose-5-and-10-mg-kg-on-stereotypies-in-trace-amine-associated.png)
Effects of apomorphine at dose 5 and 10 mg/kg on stereotypies in trace... | Download Scientific Diagram
![Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial - The Lancet Neurology Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5a5b4ae1-081c-4838-87c8-d173ef2e247b/gr1_lrg.jpg)
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial - The Lancet Neurology
![Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson's disease: A prospective analysis of Thai Apomorphine Registry - MDS Abstracts Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson's disease: A prospective analysis of Thai Apomorphine Registry - MDS Abstracts](http://www.mdsabstracts.org/wp-content/uploads/2020/09/0417_0603_001621_003.png)
Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson's disease: A prospective analysis of Thai Apomorphine Registry - MDS Abstracts
![Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study - The Lancet Neurology Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/ae7ba508-1150-4efc-8d12-ee5058e8a2f4/gr2.jpg)
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study - The Lancet Neurology
![Sunovion Pharmaceuticals Inc. - Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes Sunovion Pharmaceuticals Inc. - Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes](https://s23.q4cdn.com/866595044/files/doc_multimedia/1._KYNMOBI_Logo_highres.jpg)
Sunovion Pharmaceuticals Inc. - Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes
![Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes | Business Wire Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes | Business Wire](https://mms.businesswire.com/media/20200521005786/en/793337/5/PD_OFF-Episodes-Infographic.jpg)
Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes | Business Wire
![Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Preliminary Results from a Phase III Study - MDS Abstracts Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Preliminary Results from a Phase III Study - MDS Abstracts](https://www.mdsabstracts.org/wp-content/uploads/2017/05/0037-001034_001.jpg)
Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Preliminary Results from a Phase III Study - MDS Abstracts
![A case series of rapid titration of subcutaneous apomorphine in Parkinson's disease | British Journal of Neuroscience Nursing A case series of rapid titration of subcutaneous apomorphine in Parkinson's disease | British Journal of Neuroscience Nursing](https://www.magonlinelibrary.com/cms/10.12968/bjnn.2016.12.2.70/asset/images/medium/bjnn.2016.12.2.70_t03.jpg)
A case series of rapid titration of subcutaneous apomorphine in Parkinson's disease | British Journal of Neuroscience Nursing
![Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose - Journal of the Neurological Sciences Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose - Journal of the Neurological Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2001324459/2005135972/gr1.jpg)
Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose - Journal of the Neurological Sciences
![An updated calculator for determining levodopa-equivalent dose | Neurological Research and Practice | Full Text An updated calculator for determining levodopa-equivalent dose | Neurological Research and Practice | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs42466-021-00157-6/MediaObjects/42466_2021_157_Fig1_HTML.png)